FDA escalates warnings on compounded GLP-1 drugs, gaps remain in data
TrialSite News reports the agency's own adverse-event and inspection data leave open questions about the scale of harm from compounded semaglutide and tirzepatide.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 20 16:22 ETSource: trialsitenews.com
The wire
- 01The FDA has stepped up warnings about compounded GLP-1 products, while its underlying data on those products show important gaps, according to TrialSite News.
- 02Compounders, telehealth prescribers and patients relying on non-FDA-approved semaglutide and tirzepatide are the direct audience for the agency's messaging.
- 03The report is an analysis of agency data rather than a new enforcement action; specific counts and case details were not provided in the item.
From the source
Read at trialsitenews.comFDA Escalates Warnings on Compounded GLP-1 Drugs—but Its Own Data Reveal Important Gaps